MX2023003715A - Uso de sales de sulfato de n-(3-(4-(3-(diisobutilamino)propil)pipe razin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos de los mismos para el tratamiento de enfermedades neuronales motoras y trastornos de la union neuromuscular. - Google Patents

Uso de sales de sulfato de n-(3-(4-(3-(diisobutilamino)propil)pipe razin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos de los mismos para el tratamiento de enfermedades neuronales motoras y trastornos de la union neuromuscular.

Info

Publication number
MX2023003715A
MX2023003715A MX2023003715A MX2023003715A MX2023003715A MX 2023003715 A MX2023003715 A MX 2023003715A MX 2023003715 A MX2023003715 A MX 2023003715A MX 2023003715 A MX2023003715 A MX 2023003715A MX 2023003715 A MX2023003715 A MX 2023003715A
Authority
MX
Mexico
Prior art keywords
propyl
diisobutylamino
piperazin
imidazol
benzo
Prior art date
Application number
MX2023003715A
Other languages
English (en)
Inventor
Cécilia Estrella
Mathieu Barrier
Noëlle Callizot
Philippe Verwaerde
Original Assignee
Alzprotect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect filed Critical Alzprotect
Publication of MX2023003715A publication Critical patent/MX2023003715A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benz o[d]imidazol-2-amina y a solvatos farmacéuticamente aceptables de los mismos, para usarse en el tratamiento y/o prevención de enfermedades de las neuronas motoras y trastornos de la unión neuromuscular.
MX2023003715A 2020-10-07 2021-10-07 Uso de sales de sulfato de n-(3-(4-(3-(diisobutilamino)propil)pipe razin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos de los mismos para el tratamiento de enfermedades neuronales motoras y trastornos de la union neuromuscular. MX2023003715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20306168 2020-10-07
PCT/EP2021/077641 WO2022074093A1 (en) 2020-10-07 2021-10-07 Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders

Publications (1)

Publication Number Publication Date
MX2023003715A true MX2023003715A (es) 2023-04-24

Family

ID=73005517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003715A MX2023003715A (es) 2020-10-07 2021-10-07 Uso de sales de sulfato de n-(3-(4-(3-(diisobutilamino)propil)pipe razin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos de los mismos para el tratamiento de enfermedades neuronales motoras y trastornos de la union neuromuscular.

Country Status (10)

Country Link
US (1) US20230364076A1 (es)
EP (1) EP4225306A1 (es)
JP (1) JP7500875B2 (es)
KR (1) KR20230083330A (es)
CN (1) CN116419756A (es)
AU (1) AU2021356110A1 (es)
CA (1) CA3191189A1 (es)
IL (1) IL301633A (es)
MX (1) MX2023003715A (es)
WO (1) WO2022074093A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023117990A1 (en) * 2021-12-20 2023-06-29 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373561T3 (es) 2004-11-10 2012-02-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uso de derivados de 1,4-bis(3-aminoalquil)piperazina en el tratamiento de enfermedades neurodegenerativas.
JP6384923B2 (ja) 2012-12-27 2018-09-05 アルツプロテクト Ｎ−（３−（４−（３−（ジイソブチルアミノ）プロピル）ピペラジン−１−イル）プロピル）−１Ｈ−ベンゾ［ｄ］イミダゾール−２−アミンの硫酸塩、その製造、及びその使用
US10017476B2 (en) 2015-03-16 2018-07-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) 1,4-bis(3-aminopropyl)piperazine derivative and its use

Also Published As

Publication number Publication date
US20230364076A1 (en) 2023-11-16
JP2023544429A (ja) 2023-10-23
CA3191189A1 (en) 2022-04-14
EP4225306A1 (en) 2023-08-16
KR20230083330A (ko) 2023-06-09
JP7500875B2 (ja) 2024-06-17
AU2021356110A1 (en) 2023-03-16
WO2022074093A1 (en) 2022-04-14
IL301633A (en) 2023-05-01
CN116419756A (zh) 2023-07-11

Similar Documents

Publication Publication Date Title
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
CA2615271C (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
ATE384724T1 (de) Cyclopropylverbindungen als ccr5 antagonisten
MXPA02008064A (es) Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis.
NO20061454L (no) Compounds having CRTH2 antagonist activity
NZ333436A (en) Piperazinyl-heterocyclic compounds for treating psychiatric conditions
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
MX2023003715A (es) Uso de sales de sulfato de n-(3-(4-(3-(diisobutilamino)propil)pipe razin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos de los mismos para el tratamiento de enfermedades neuronales motoras y trastornos de la union neuromuscular.
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
CY1107204T1 (el) Πιπεραζινοβενζοθειαζολια ως ουσιες για την θεραπευτικη αντιμετωπιση εγκεφαλικων ισχαιμικων διαταραχων ή διαταραχων του κνς
EP1626722A1 (en) Method for enhancing cognition using ziprasidone
MX363367B (es) Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.
ATE369861T1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
IL202047A (en) Trans-4- {2- [4 [(3,2-dichlorophenyl) -piperazine-1-yl] -ethyl} - n-n-dimethylcarbamoyl-cyclohexylamine for use in the treatment of schizophrenia
FR2856596B1 (fr) Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
ES2147616T3 (es) Derivados de piperidina con actividad antagonista del paf.
MY129224A (en) 4-phenyl-pyridine derivatives
RU2011109078A (ru) Лечение легочной артериальной гипертензии
JP2005506982A5 (es)
ZA202206837B (en) Compounds for treatment of alzheimer's disease
EP1626723A1 (en) Treatment of bipolar disorders and associated symptoms
MX2023003878A (es) Sales de succinato de n-(3-(4-(3-(diisobutilamino)propil)piperazin -1-il)propil)-1h-benzo[d]imidazol-2-amina, preparacion de las mismas y uso de las mismas.
NO20070878L (no) Dimere piperidinderivater
JOP20210275A1 (ar) مشتقات 3-أمينو-4h-بنزو[e][4,2,1]ثيادايازين 1,1-داي أكسيد كمثبطات لـ mrgx2
AU2022422257A1 (en) USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS